

Substitute for form 1449A/PTO
**INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT**
 (Use as many sheets as necessary)

COPY

PTO/509 (10-01)
 Approved for use through 10/31/2002, OAS 651-001
 US Patent & Trademark Office U.S. DEPARTMENT OF COMMERCE
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OASD control number.

Complete if Known

Application Number 09/866458
 Filing Date May 25, 2001
 First Named Inventor Meadows Ph.D., Gary
 Group Art Unit 1614
 Examiner Name Goldberg, Jerome

Sheet 1 of 2

Attorney Docket No: 00618.002US1

US PATENT DOCUMENTS

Examiner Initials *	Cite No	USP Document No	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures appear
RL		US-3561444	02/09/1971	Boucher	
		US-3703173	11/21/1972	Dixon, T. A.	
		US-4051842	10/04/1977	Hazel, P. M., et al	
		US-4140122	02/20/1979	Kuhl, D., et al	
		US-4383529	05/17/1983	Webster, H. L.	
		US-4624251	11/25/1986	Miller, N. C.	
		US-4635627	10/09/1990	Eppstein, D. A., et al	
		US-4962091	10/09/1990	Eppstein, D. A., et al	
		US-5560922	10/01/1996	Chlen, Y. W., et al	
		US-5879712	03/09/1999	Bomberger, et al	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures appear
RL		WO-94/07529	04/14/1994	Kunz	

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T*
RL		ABDUL, M., et al., "Growth-Inhibitory Effects of Serotonin uptake Inhibitors on Human Prostate Carcinoma Cell Lines", <u>The Journal of Urology</u> , 154, (1995), pp. 247-250	
		BRANDES, L.J., et al., "Stimulation of Malignant Growth in Rodents by Antidepressant Drugs at Clinically Relevant Doses", <u>Cancer Research</u> , 52, (1992), pp. 3496-3800	
		IKEN, K., et al., "Serotonin Upregulates Mitogen-Stimulated B Lymphocyte Proliferation through 5-HT1A Receptors", <u>Cellular Immunology</u> , 163, (1995), pp. 1-9	
		JOKI, T., et al., "Continuous release of endostatin from microencapsulated engineered cells for tumor therapy", <u>Nature Biotechnology</u> , 19, (Jan. 2001), pp. 35-39	
		LIU, Y., et al., "Haloperidol and spiperone potentiate murine splenic B cell proliferation", <u>Immunopharmacology</u> , 34, (1996), pp. 147-159	
		MERZAK, A., et al., "Expression of serotonin receptors in human fetal astrocytes and glioma cell lines: a possible role in glioma cell proliferation and migration", <u>Molecular Brain Research</u> , 41, (1996), pp. 1-7	
		NEWMAN, S.P., "Chapter 9: Therapeutic aerosols", In: <u>Aerosols and the Lung: Clinical and Experimental Aspects</u> , Stewart W. Clarke, et al., Eds., Butterworths	

EXAMINER

DATE CONSIDERED

2/7/05

Substitute Disclosure Statement Form (PTO-1449)
 * EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with non-communication to applicant. * Applicant's unique citation designation number (optional). * Applicant is to place a check mark here if English language Translation is attached.

B

Substitute for form 1448A/PTO
**INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT**
 (Use as many sheets as necessary)

COPY

Under the Patent Reform Act of 1995, no person is required to respond to a collection of information unless it carries a valid OMB control number.

PTO/USPO/004(10-01)
 Approved for use through 10/31/2002, OMB 0591-0001
 US Patent & Trademark Office U.S. DEPARTMENT OF COMMERCE

Complete if Known	
Application Number	09/866458
Filing Date	May 25, 2001
First Named Inventor	Meadows Ph.D., Gary
Group Art Unit	1614
Examiner Name	Goldberg, Jerome

Sheet 2 of 2

Attorney Docket No: 00618.002US1

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T*
		(Publisher), (1984), pp. 197-224	
RL		PAKALA, R., et al., "Effect of Serotonin, Thromboxane A2, and Specific Receptor Antagonists on Vascular Smooth Muscle Cell Proliferation", <u>Circulation</u> , 96 (7), (1997), pp. 2280-2286	
		SHEEHAN, P.F.J., et al., "Effects of Histamine and 5-Hydroxytryptamine on the Growth Rate of Xenografted Human Bronchogenic Carcinomas", <u>Clinical and Experimental Pharmacology and Physiology</u> , 23, (1996), pp. 485-471	
		STEINGART, A.B., et al., "Do Antidepressants Cause, Promote, or Inhibit Cancers", <u>J. Clin. Epidemiol.</u> , 48 (11), (1995), pp. 1407-1412	
		UEHARA, Y., et al., "Antiproliferative Effects of the Serotonin Type 2 Receptor Antagonist, Ketanserin, on Smooth Muscle Cell Growth in Rats", <u>Journal of Cardiovascular Pharmacology</u> , 17 (Suppl. 2), (1991), pp. S154-S156	
		WESTPHAL, R.S., et al., "Differences in Agonist-Independent and -Dependent 5-Hydroxytryptamine _{2C} Receptor-Mediated Cell Division", <u>Molecular Pharmacology</u> , 49, (1996), pp. 474-480	
		YOUNG, M.R.I., et al., "Stimulation of splenic T-lymphocyte function by endogenous serotonin and by low-dose exogenous serotonin", <u>Immunology</u> , 80, (1993), pp. 395-400	
		ZACHRISSON, K., et al., "Serotonin and neuroendocrine peptides influence DNA synthesis in rat and human small intestinal cells in vitro", <u>Acta Physiol. Scand.</u> , 163, (1998), pp. 195-200	

EXAMINER

Amy A. Lewis

DATE CONSIDERED

2/7/05

Substitute Disclosure Statement Form (PTO-1442)
 * EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 802. One line through citation if not in conformance and not considered. Include copy of this form with each communication to applicant. Applicant: Indicate citation designation number (optional). Applicant to place a check mark here if English language translation is attached.